Amphastar Pharmaceuticals, Inc. (AMPH) vs CeriBell, Inc. (CBLL)
A side-by-side comparison of Amphastar Pharmaceuticals, Inc. and CeriBell, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMPH
Amphastar Pharmaceuticals, Inc.
$25.43HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
CBLL
CeriBell, Inc.
$24.46HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — AMPH vs CBLL
growth of $100 · dividends reinvested · last 2yAMPH -46.7% (-27.0%/yr)CBLL -0.6% (-0.3%/yr)CBLL compounded faster over this window
AMPH CBLL
AMPH vs CBLL: by the numbers
- •AMPH is the larger company ($1.12B vs $928M market cap).
- •AMPH is profitable (10.76% net margin) while CBLL runs a net loss (-64.73%).
Metrics side by side
Valuation
| Metric | AMPH | CBLL |
|---|---|---|
| P/E ratio | 15.05 | N/A |
| Forward P/E | 8.56 | N/A |
| PEG ratio | 0.11 | N/A |
| P/S ratio | 1.54 | 9.10 |
| P/B ratio | 1.46 | 7.23 |
| EV / EBITDA | 8.84 | N/A |
| FCF yield | 13.64% | N/A |
Profitability
| Metric | AMPH | CBLL |
|---|---|---|
| Gross margin | 47.68% | 88.90% |
| Operating margin | 15.66% | -68.62% |
| Net margin | 10.76% | -64.73% |
| ROE | 10.23% | -51.43% |
| ROIC | 5.93% | -46.54% |
Growth (annualized)
| Metric | AMPH | CBLL |
|---|---|---|
| Revenue CAGR (5Y) | 13.71% | N/A |
| EPS CAGR (5Y) | 134.23% | N/A |
| FCF CAGR (5Y) | 23.90% | N/A |
| Total return CAGR (5Y) | 6.13% | N/A |
Frequently asked
- Is AMPH or CBLL more profitable?
- AMPH runs the higher net margin — AMPH at 10.76% versus CBLL at -64.73%.
Go deeper
Dig into the metrics
Amphastar Pharmaceuticals P/E ratioAmphastar Pharmaceuticals ROECeriBell ROEAmphastar Pharmaceuticals operating marginCeriBell operating marginAmphastar Pharmaceuticals revenue growthCeriBell revenue growthAmphastar Pharmaceuticals free cash flowCeriBell free cash flow
Amphastar Pharmaceuticals & CeriBell appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.